Abacus acquisition to boost Piramal’s market access capabilities
This article was originally published in Scrip
Executive Summary
Just over six months after its acquisition of the US-based healthcare information business firm Decision Resources Group (DRG), the Piramal group has added the UK-based Abacus International, a provider of evidence-based global market access solutions, to its fold.
You may also be interested in...
Piramal Profits As It Sheds DRG To Clarivate For $950m
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.